Company intelligence / Profile preview
Sirius Therapeutics
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Sirius Therapeutics has three clinical-stage programs targeting cardiometabolic diseases using proprietary siRNA technology. The most advanced candidate, SRSD107, targets Factor XI for thromboembolic disorders and is entering Phase II trials. Other candidates are advancing through early clinical development with a focus on infrequent dosing and improved patient outcomes. The company has raised nearly $150 million to date.
- Therapeutic areas
- CardiovascularEndocrinologyHematology
- Modalities
- siRNARNAi
- Industry
- Biotech
02
Drug pipeline
22 assets21 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Sirius Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sirius Therapeutics.